Aurinia Pharmaceuticals | 4:持股變動聲明-董事 TANG KEVIN
Aurinia Pharmaceuticals | 4:持股變動聲明-董事 Smith Karen L.
Aurinia Pharmaceuticals | 4:持股變動聲明-董事 Leversage Jill
Aurinia Pharmaceuticals | 4:持股變動聲明-董事 Johnson Craig A
Aurinia Pharmaceuticals | 4:持股變動聲明-董事 Bailey Jeffrey Allen
Aurinia Pharmaceuticals | 4:持股變動聲明-董事 Jayne David R.W.
Aurinia Pharmaceuticals | SC 13G/A:超過5%持股股東披露文件(修正)-Armistice Capital, LLC(5.73%),Steven Boyd(5.73%)
Aurinia Pharmaceuticals | 4:持股變動聲明-董事 Bailey Jeffrey Allen
Aurinia Pharmaceuticals | 4:持股變動聲明-董事 Smith Karen L.
Aurinia Pharmaceuticals | 3:首次持股聲明-高管 Keenan Greg
Aurinia Pharmaceuticals | 3:首次持股聲明-董事 Johnson Craig A
Aurinia Pharmaceuticals | 10-Q:2024財年三季報
Aurinia Pharmaceuticals | 8-K:Aurinia Pharmicals 公佈了 2024 年第三季度和九個月的財務和經營業績,宣佈進行戰略重組,以進一步關注 LUPKYNIS® 的持續增長和 AUR200 的發展
Aurinia Pharmaceuticals | 3:首次持股聲明-董事 TANG KEVIN
Aurinia Pharmaceuticals | 4:持股變動聲明- MacKay-Dunn R. Hector
Aurinia Pharmaceuticals | SC 13D:超過5%持股股東披露文件-TANG CAPITAL MANAGEMENT, LLC(5.1%),KEVIN TANG(5.1%)等
Aurinia Pharmaceuticals | 8-K:重大事件
Aurinia Pharmaceuticals | 4:持股變動聲明-高管 Habig Scott Michael
Aurinia Pharmaceuticals | 8-K:AURINIA PHARMICALS公佈2024年第二季度和六個月的財務和運營業績
Aurinia Pharmaceuticals | 10-Q:2024財年二季報